Chinese drug makers are heading for the big leagues, getting closer to establishing a foothold in the global marketplace. Companies like Jiangsu Hengrui Pharmaceuticals are landing big deals with Western companies like GSK, but entry barriers remain. In particular, China-based companies lack experience on the commercial side of the U.S. market.
“China has world-class technology and world-class drugs that are already reaching patients. That's already transforming patient experience globally,” said John Barry, executive vice president of corporate development and strategy at SAI. “The next step, I think, for Chinese companies is to capture that value rather than letting multinational companies capture that value.”
The 30 top Chinese pharmaceutical companies generated $37.7 billion in global revenue in 2025, gained approval for 30 innovative drugs and invested approximately $8.5 billion in R&D, according to the 2026 China Pharmaceutical Innovation and Invention Index from SAI MedPartners.
“We're seeing a dramatic increase in invention coming out of China, and that innovative drug development is being recognized globally,” Barry said.
But to cement their international presence, Chinese drug makers will need to navigate three different stages, according to Celia Deng, Asia president at SAI — secure deals, develop global clinical development capabilities, and effectively sell their drugs.
“The U.S. payer system is very challenging, very unique. And there are a lot of different ways to approach access.”

John Barry
EVP, corporate development and strategy, SAI
Most Chinese companies are currently in stage one, heading into stage two, according to SAI. Market leaders will likely make it to stage three in the next three to five years, SAI predicts.
China’s rising stars
Hengrui is a frontrunner among the Chinese pharmas moving into international circles. In 2024, it surpassed AstraZeneca as the world’s leading clinical trial sponsor, according to Citeline data. Hengrui also ranked first in both innovation and invention on SAI’s innovation index for its substantial investment in R&D, which totaled RMB 8.724 billion, or roughly $1.21 billion, in 2025, and innovative drug sales of RMB 16.342 billion, or around $2.27 billion.
“In 2025, the company completed five overseas business development transactions for innovative drugs, generating out-licensing revenue of RMB 3.392 billion,” according to the index.
These deals included a multi-asset collaboration with GSK that could be worth up to $12 billion, a licensing agreement with Merck, and smaller licensing pacts to advance other drug assets.
Other China-based companies are also making headway, including CSPC Pharmaceutical Group, which ranked second on the index in invention and eighth in innovation. It was recognized for its international partnerships linked to both the company’s assets and technology platforms.
Innovent also got a mention for its global collaborations with Takeda Pharmaceuticals and Roche.
Overcoming global barriers
While many Chinese companies are still heavily focused on their domestic drug market, they are increasingly branching out.
“For Chinese companies to be successful, they also have to understand the importance of going global,” Deng said.
Historically, over half of the revenue from innovative drugs has come from the U.S. market, Barry said. But there’s a steep learning curve when it comes to breaking into the U.S. market.
“And so you have to understand what it means to launch in the U.S.,” he said. “The U.S. payer system is very challenging, very unique. And there are a lot of different ways to approach access.”
There are some major differences between the Chinese and U.S. health systems. For example, the Chinese system is quite consolidated. In China, patients seeking innovative drugs often travel to big hospitals in big cities, Deng said. That’s not always the case in the U.S., where community physicians often play a leading role in prescribing.
“It’s not driven in a centralized manner from the academic centers in the U.S. as much as it is in China,” Barry said.
Pharma companies not only need to get their messaging to patients who take the drugs, but also to physicians, including community physicians, who are actually going to drive uptake by writing prescriptions, Barry said.
“Many Chinese companies don’t have overseas commercialization teams, so there’s a long way to go. But the ambition is there,” Deng said.
To make the leap, Chinese companies are increasingly forging ties with those who have experience commercializing drugs for the U.S. market.
They are also focused on building trust in their science. The issue is especially salient because there have been times when the data generated in China has not translated to a global patient population, Barry said.
“Sometimes there are biological differences in the Chinese population. Sometimes there are treatment practice differences in the local China population,” he said.
But trials are becoming more global, helping drug developers overcome some of the concerns about how research findings will translate to a wider population. Increasingly, China-based companies are initiating trials in the U.S., the EU, and China at roughly the same time.
“Nowadays, they all understand if they want to do big deals with multinational corporations, they have to have global data as well,” Deng said.
Political headwinds arise
Not everyone in the U.S. is welcoming China’s rise. Some Congressional leaders have become increasingly concerned about the competitive threat the nation poses to the U.S. drug development industry, as well as potential security risks.
Those concerns have triggered several legislative and regulatory actions, including proposed Treasury rules under the COINS Act, which could limit certain U.S. investments in Chinese biotechs. Lawmakers also requested more FDA oversight of China-generated data after delayed reporting of three patient deaths in Chinese trials. And the U.S. enacted the Biosecure Act last year, which will restrict federal procurement and federally funded work involving designated biotechnology companies of potential concern to national security.
Still, it’s unlikely that these efforts will provide a lasting drag on China’s rise, according to Deng. Like a river, Chinese momentum could weave its way around obstacles rather than be halted by them.
“Globalization is unstoppable,” Deng said. “There are a lot of political challenges going on and it may bring some obstacles in a short period of time, but I don't really think that can change anything in the long term.”